Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

Measures of kidney function may be linked to thrombosis

Estimated glomerular filtration rate and albumin-creatinine ratio are independently associated with venous thromboembolism, research suggests.

18 Sep 2012

Measures of kidney function may be linked to thrombosis

Estimated glomerular filtration rate and albumin-creatinine ratio are independently associated with venous thromboembolism, research suggests.

18 Sep 2012

Apixaban offers minor added benefit for adult patients after hip replacement

The clot-inhibiting drug apixaban was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint.

18 Sep 2012

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.

18 Sep 2012

Genetic test to help prescribe proper dose of blood-thinner warfarin

Patients suffering from dangerous blood clots will receive genetic testing to help health professionals at the University of Illinois Hospital & Health Sciences System prescribe the proper dose of the blood-thinner warfarin.

7 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Some smaller clots may not require potentially risky treatment

Men and women who undergo joint replacement procedures, as well as those who have significant fractures, tend to be at an increased risk of developing pulmonary emboli (PE), blood clots that travel to the lungs where they may cause serious complications and even death.

1 Sep 2012

ICU misdiagnosis alarmingly common in the acute care setting

Each year as many as 40,500 critically ill U.S. hospital patients die with an unknown medical condition that may have caused or contributed to their death, Johns Hopkins patient safety experts report in a recent study.

28 Aug 2012

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

An international multi-site trial has launched to determine whether a common anti-inflammatory drug can reduce heart attacks, strokes, and deaths due to cardiovascular disease in people at high risk for them. This study is being supported by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health.

22 Aug 2012

Low blood anticoagulant levels increase risk for VTE

Low plasma levels of antithrombin, protein C, and protein S significantly increase the risk for venous thromboembolism, Italian research shows.

25 Jul 2012

Knee surgery blood loss reduced with single tranexamic acid dose

A single intraoperative dose of tranexamic acid is effective at reducing blood loss in patients undergoing minimally invasive total knee arthroplasty, research suggests.

20 Jul 2012

Kawasaki Disease may increase risk of atherosclerosis in children

Cedars-Sinai researchers have linked Kawasaki Disease, a serious childhood illness that causes inflammation of blood vessels throughout the body, with early-onset and accelerated atherosclerosis, a leading cause of heart disease in adults.

18 Jul 2012

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%.

17 Jul 2012

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

The Vanderbilt Heart and Vascular Institute (VHVI) now offers a minimally invasive, catheter-based approach to dissolving pulmonary embolism, a potentially life-threatening blood clot that form elsewhere in the body and travels into the lungs.

17 Jul 2012

SLU professor to study how antithrombin might prevent premature death from heart disease

Alireza "Ray" Rezaie, Ph.D., professor of biochemistry and molecular biology at Saint Louis University School of Medicine, has received a $1.52 million NIH grant to study how the key blood clotting inhibitor antithrombin might be exploited to prevent premature death from heart disease.

12 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Novel biomimetic strategy can dissolve blood clots before they cause serious damage or even death

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a novel biomimetic strategy that delivers life-saving nanotherapeutics directly to obstructed blood vessels, dissolving blood clots before they cause serious damage or even death.

6 Jul 2012

Covidien introduces campaign to help educate women about risk of VTE during pregnancy

Covidien, a leading global provider of healthcare products, today announced the launch of its "1 in 1,000" campaign to help educate women about the risk of pregnancy-related blood clots, one of the leading causes of maternal mortality in the developed world.

28 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

A third of ED imaging for PE is avoidable

Data from 12 hospitals in the USA indicate that one-third of imaging performed in the emergency department for suspected pulmonary embolism is avoidable, according to a National Quality Forum measure.

15 Jun 2012